University of Lethbridge Researchers Pioneer New Insights into RNA's Role in Fueling Cancer Growth
At the University of Lethbridge in Alberta, Canada, a team of biochemists has made a groundbreaking discovery that sheds light on how cancer cells harness energy to proliferate uncontrollably. Led by Drs. Trushar Patel and Higor Sette Pereira, the research reveals the pivotal function of a long non-coding ribonucleic acid (lncRNA) called RMRP in maintaining mitochondrial health—the powerhouse of the cell essential for cancer's rapid growth.
This foundational work, published in the prestigious Proceedings of the National Academy of Sciences (PNAS) on February 20, 2026, marks the first visualization of RMRP's three-dimensional structure and uncovers its interactions with key proteins that direct it to mitochondria. By disrupting RMRP, scientists observed mitochondrial stress and elevated reactive oxygen species (ROS), weakening cancer cells without halting normal cell growth.
The implications are profound for treating aggressive cancers where RMRP levels are sky-high, offering a novel target to sensitize tumors to existing therapies. As Canada grapples with rising cancer rates—expected to see over 240,000 new diagnoses in 2026—this research from a mid-sized prairie university underscores the nation's innovative higher education landscape.
Meet the Minds Behind the Discovery: Patel, Pereira, and Collaborative Excellence
Dr. Trushar Patel, a Professor and Canada Research Chair in RNA and Protein Biophysics at the University of Lethbridge, brings interdisciplinary expertise to the table. With over 6,200 citations on Google Scholar, Patel's lab specializes in biophysical techniques to decode RNA-protein interactions, previously focused on viral-host dynamics but now pivoting to cancer biophysics. As Associate Dean, he champions student involvement, noting, "This is foundational research—one of the first on RMRP's mitochondrial role—opening doors for future biomedical advances."
Postdoctoral researcher Higor Sette Pereira led the structural analyses, stating, "We identified RMRP's 3D envelope for the first time, revealing how its absence compromises mitochondrial bioenergetics." Collaborator Dr. Harpreet Singh from Ohio State University contributed functional assays, highlighting, "RMRP removal triggers ROS, damaging cells and linking to disease."
This international partnership exemplifies how the University of Lethbridge fosters global ties, training the next generation through hands-on projects. For aspiring researchers, opportunities abound in higher ed research assistant jobs at Canadian institutions like this.
Demystifying RMRP: From Ribosomal Processing to Cancer's Energy Secret Weapon
RMRP, or RNA component of mitochondrial RNA processing endoribonuclease, is a lncRNA—a type of non-protein-coding RNA longer than 200 nucleotides that regulates gene expression. Traditionally known for cleaving ribosomal RNA (rRNA) precursors in the nucleus, this study unveils its moonlighting role in mitochondria.
Using small-angle X-ray scattering (SAXS), the team showed RMRP adopts Mg²⁺-dependent shapes: an extended Y-form at low magnesium (230 Å) shifting to compact (180 Å) at high levels, exposing binding sites for proteins like RPP20-RPP25. It interacts with DEAD-box helicases DDX5 (high-affinity binder with ATP-dependent unwinding) and DDX3X (expression regulator), shuttling RMRP to mitochondria.
- DDX5: Strong binding (K_D 1.38 μM), remodels RMRP structure.
- DDX3X: Moderate binding (K_D 7.06 μM), upstream regulator reducing RMRP by 40% upon knockdown.
- Network: Compensatory factors like HuR and GRSF1 maintain balance.
Cancer cells, proliferating 10-100x faster than normal, crave mitochondrial ATP. RMRP sustains this by regulating nuclear-encoded proteins DNAJC11 (cristae structure) and NDUFS8 (respiratory chain), preventing dysfunction.
Experimental Breakthroughs: Visualizing Structure and Disrupting Mitochondria
The study's rigor combined biophysics, proteomics, and cell biology. RNA pull-downs in prostate cancer PC-3M cells (high RMRP expressers) identified partners enriched in ribosome biogenesis and oxidative phosphorylation. Knockdowns via siRNA showed:
| Intervention | Mitochondrial Effects | Quantified Change |
|---|---|---|
| RMRP depletion | Membrane depolarization, ROS surge, cristae fragmentation | JC-1 ratio ↓35%, Complex IV ↓32%, DNAJC11 ↓60%, NDUFS8 ↓45% |
| DDX5 knockdown | Reduced mito RMRP (25% remaining) | Morphology altered |
| DDX3X knockdown | Mito RMRP ↓50%, Mg²⁺ ↓37% | Network upregulation |
Fluorescence in situ hybridization (FISH) with MitoTracker confirmed localization; no proliferation/apoptosis changes suggest cancer adaptation potential. Read the full PNAS paper for figures like SAXS models and ROS assays.
RMRP's Dark Side: Overexpressed in Canada's Top Cancers, Linked to Poor Prognosis
RMRP upregulation correlates with dismal outcomes in breast (28,600 new cases projected 2026), lung (30,000+), prostate (25,500), and colorectal (27,000) cancers—Canada's big four, comprising ~48% of diagnoses. In aggressive lines like PC-3M, it's 4.7-fold elevated, fueling survival via healthy mitochondria.
Past studies link RMRP mutations to cancer predisposition (e.g., cartilage-hair hypoplasia), and oncogenic roles in HCC, ovarian, cholangiocarcinoma via miRNA sponging or PARP resistance. Patel notes, "High RMRP gives cancer a survival edge—targeting it could level the field."
For Canadian patients, where lung cancer kills 20,700 yearly, such insights promise precision oncology.
Toward Therapies: Weakening Cancer via RMRP Inhibition
Knocking down RMRP induces selective mitochondrial vulnerability—ideal for combination therapies. Prospects include antisense oligonucleotides (ASOs) or siRNAs, mirroring successes like inclisiran for lipids. Canada leads RNA therapeutics: MUHC's mRNA bladder cancer trial, U Toronto's TITUR nanomedicine for personalized mRNA vaccines.
- Short-term: Dampen RMRP to boost ROS sensitivity in chemo/radiotherapy.
- Long-term: CRISPR or small molecules targeting DDX5/RMRP complex.
- Challenges: Delivery to mitochondria, off-targets in normal cells.
Sette Pereira envisions, "Altering RMRP could make tumors vulnerable to standard treatments." Explore career advice for RNA researchers.
University of Lethbridge: A Hub for Cutting-Edge Cancer Research in Alberta
Beyond Patel's lab, U Lethbridge boasts the Cancer Cell Laboratory and initiatives like Thakor's glioblastoma probes and Kovalchuk's epigenetic studies—miRNA-34a/tRNA interactions. As Patel affirms, "Proven research happens here, not just in big cities." Alberta's Research Chairs amplify this, with NSERC funding biophysics.
Students thrive; check Rate My Professor reviews for Patel's engaging biophysics courses.
Canada's Momentum in Non-Coding RNA Cancer Research
U Lethbridge joins leaders: U Toronto maps lncRNAs in testes/prostate; Laval's lncRNA controls ribosome biogenesis; OICR probes ncRNAs in leukemia. RNA Canada's 2024 clinic stories highlight mRNA vaccines' pivot to oncology. D2R's $10M funds RNA therapies for rare cancers.
With 86,700 cancer deaths yearly, these efforts position Canada as a ncRNA powerhouse.
Challenges, Opportunities, and the Road Ahead
Hurdles: lncRNA targeting specificity, mitochondrial delivery. Yet, post-COVID mRNA tech accelerates trials—e.g., TransCode's miR-10b inhibitor. Future: Validate in patient models, expand to pan-cancer screens.
Patel's vision: "Basic biology fuels therapies." For careers, faculty positions in Canadian biochem await.
Photo by National Cancer Institute on Unsplash
A Beacon for Hope in Canada's Fight Against Cancer
The U Lethbridge RMRP breakthrough exemplifies higher ed's role in health innovation. By targeting cancer's energy lifeline, it paves personalized paths. Stay informed via higher education news; explore Rate My Professor, higher ed jobs, career advice, university jobs, or Canadian academic opportunities. Share your thoughts below—what excites you most?
%20Logo.png&w=128&q=75)
